Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05087758
Other study ID # CR-21-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date March 30, 2024

Study information

Verified date May 2023
Source LifeNet Health
Contact Barry Saxton, PA-C
Phone 404 314 4903
Email barry_saxton@lifenethealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below: 1. Be male or female, between 21 and 80 years of age at the time of consent 2. For subjects with a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit 3. Have a full-thickness wound of the lower extremity 4. Have a single target ulcer 5. Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm 6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2: - Grade 1: superficial diabetic ulcer including the full skin thickness but not underlying tissue - Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess of osteomyelitis 7. Have an absence of infection based on Infectious Disease Society of America criteria 8. Have an adequate circulation to the affected lower extremity, defined as at least one these criteria: - Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg - Ankle-brachial index (ABI) greater than 0.75 - At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries 9. Have the ability to comply with off-loading (if required for specific wound) and dressing change requirements 10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments 11. Have provided written authorization for use and disclosure of protected health information 12. Have a life expectancy of greater than 6 months Exclusion Criteria: To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below: 1. Be pregnant or lactating 2. Have a wound that decreased in size =50% between the Screening and Baseline Visits 3. Have circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit 4. Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening 5. Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin B Sulfate, and/or Vancomycin 6. Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase® 7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit 8. Need for any additional concomitant dressing material other than the ones approved for this study 9. Have clinical signs of an infection at the study ulcer site 10. Have the inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast) 11. Have a known or suspected disease of the immune system 12. Have an active or untreated malignancy or active, uncontrolled connective tissue disease 13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the baseline visit 14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement 15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit 16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening 17. Have evidence of active Charcot disease 18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening 19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot 20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Matrion
Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
Conventional Care Wound Management
Advanced wound care with debridement and dressings

Locations

Country Name City State
United States Albuquerque Associated Podiatrists Albuquerque New Mexico
United States Center for Clinical Research, INC Carmichael California
United States Limb Preservation Platform, INC Fresno California
United States Doctors Research Network Miami Florida
United States Purvis-Moyer Foot and Ankle Center Rocky Mount North Carolina
United States ILD Research Center San Diego California
United States Center for Clinical Research, INC San Francisco California
United States Compass Medical Research Center, LLC Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
LifeNet Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound Healing Proportion of chronic DFUs that have achieved complete wound closure 12 weeks
Secondary Speed of Wound Closure Time to wound closure measured from the baseline visit to the termination visit 12 weeks
Secondary Wound Area Change in wound area over time 12 weeks
Secondary Infection Rate of wound infection 12 weeks
Secondary Reoccurrence Rate of reoccurrence of wound post treatment 6 months post termination visit
Secondary Grafts Used Average number of Matrion grafts used per subject 12 weeks
Secondary Incidence of Treatment Emergent Adverse Events Collection of adverse events, including changes in vital signs, ABI, and physical exams 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06154915 - Immune Cells in Diabetic Chronic Foot Ulcers
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Completed NCT02373592 - Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer N/A
Active, not recruiting NCT01903044 - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating Phase 1/Phase 2
Completed NCT02092870 - Adipose Derived Regenerative Cellular Therapy of Chronic Wounds Phase 2
Completed NCT01212120 - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections N/A
Completed NCT00402727 - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection Phase 3
Recruiting NCT04085705 - The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Completed NCT04480801 - The Effect of Thermal Evaluation in Prevention of Diabetic Foot Ulcer N/A
Not yet recruiting NCT04537676 - Patient Empowerment Study
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A
Recruiting NCT05974592 - The Effect of Nurse-Led Diabetic Foot Self-Management Training Program N/A
Not yet recruiting NCT04630795 - ViscoTurf - Preventing Secondary Diabetic Foot Ulceration.
Not yet recruiting NCT05431660 - Diabetic Foot School and Biomechanics N/A
Completed NCT05101473 - Exercise Therapy for People With a Diabetic Foot Ulcer - a Feasibility Study N/A
Completed NCT05123157 - Pattern and Type of Amputation and Mortality Rate Associated With Diabetic Foot in Jeddah, Saudi Arabia: A Retrospective Cohort Study
Enrolling by invitation NCT05043636 - Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
Completed NCT03254095 - Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.